HURDLES TO REIMBURSEMENT FOR GLP-1 THERAPIES IN WEIGHT MANAGEMENT

被引：0
|
作者：
Stanley, A. [1 ]
Nisar, S. [2 ]
Rowlands, C. [2 ]
机构：
[1] Envis Pharma Grp, London, England
[2] Envis Pharma Grp, Horsham, W Sussex, England
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
HTA7
引用
收藏
页码：S354 / S354
页数：1
相关论文
共 50 条
  • [31] Side effects of GLP-1 agonists as weight loss aids
    不详
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2023, 148 (23) : 1482 - 1482
  • [32] Is the GLP-1 system a viable therapeutic target for weight reduction?
    Tong, Jenny
    Sandoval, Darleen A.
    REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, 2011, 12 (03): : 187 - 195
  • [33] Semaglutide and GLP-1 analogues as weight-loss agents
    Kluger, Aaron Y.
    McCullough, Peter A.
    LANCET, 2018, 392 (10148): : 615 - 616
  • [34] After GLP-1, what's next for weight loss?
    Senior, Melanie
    NATURE BIOTECHNOLOGY, 2023, 41 (06) : 740 - 740
  • [35] Implications of GLP-1 agonist use on airway management
    Mizubuti, Glenio B.
    Ho, Anthony M. -H.
    da Silva, Leopoldo Muniz
    AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2024, 82 : 190 - 191
  • [36] GLP-1 receptor agonists beyond diabetes management
    不详
    ECLINICALMEDICINE, 2024, 78
  • [37] GLP-1 in NIDDM
    Holst, JJ
    DIABETIC MEDICINE, 1996, 13 (09) : S156 - S160
  • [38] GLP-1 and the gut
    Thompson, DG
    GUT, 2000, 46 (05) : 591 - 591
  • [39] Obesity and GLP-1
    De Oca, Alejandra Perez-Montes
    Pellitero, Silvia
    Puig-Domingo, Manel
    MINERVA ENDOCRINOLOGY, 2021, 46 (02): : 168 - 176
  • [40] The extent and predictors of off-label use of GLP-1 receptor agonists for weight loss management
    Siudak, Zbigniew
    Tkaczyk, Filip
    Tomaszewska, Monika
    Malinowski, Krzysztof P.
    Szarpak, Lukasz
    Kowalska-Bobko, Iwona
    DIABETES OBESITY & METABOLISM, 2025,
12345